Back to top
more

PRESTIGE CONSMR (PBH)

(Delayed Data from NYSE)

$73.53 USD

73.53
205,757

-0.02 (-0.03%)

Updated Sep 18, 2024 04:00 PM ET

After-Market: $73.51 -0.02 (-0.03%) 6:40 PM ET

Zacks Rank:

This is our short term rating system that serves as a timeliness indicator for stocks over the next 1 to 3 months. How good is it? See rankings and related performance below.

Zacks Rank Definition Annualized Return
1Strong Buy23.68%
2Buy17.55%
3Hold9.21%
4Sell4.93%
5Strong Sell2.36%
S&P50010.96%

Zacks Rank Education - Learn about the Zacks Rank

Zacks Rank Home - Zacks Rank resources in one place

Zacks Premium - The only way to fully access the Zacks Rank

2-Buy of 5   2      

Style Scores:

The Style Scores are a complementary set of indicators to use alongside the Zacks Rank. It allows the user to better focus on the stocks that are the best fit for his or her personal trading style.

The scores are based on the trading styles of Value, Growth, and Momentum. There's also a VGM Score ('V' for Value, 'G' for Growth and 'M' for Momentum), which combines the weighted average of the individual style scores into one score.

Value Score A
Growth Score A
Momentum Score A
VGM Score A

Within each Score, stocks are graded into five groups: A, B, C, D and F. As you might remember from your school days, an A, is better than a B; a B is better than a C; a C is better than a D; and a D is better than an F.

As an investor, you want to buy stocks with the highest probability of success. That means you want to buy stocks with a Zacks Rank #1 or #2, Strong Buy or Buy, which also has a Score of an A or a B in your personal trading style.

Zacks Style Scores Education - Learn more about the Zacks Style Scores

A Value D Growth D Momentum C VGM

Industry Rank:

The Zacks Industry Rank assigns a rating to each of the 265 X (Expanded) Industries based on their average Zacks Rank.

An industry with a larger percentage of Zacks Rank #1's and #2's will have a better average Zacks Rank than one with a larger percentage of Zacks Rank #4's and #5's.

The industry with the best average Zacks Rank would be considered the top industry (1 out of 265), which would place it in the top 1% of Zacks Ranked Industries. The industry with the worst average Zacks Rank (265 out of 265) would place in the bottom 1%.

Zacks Rank Education -- Learn more about the Zacks Rank
Zacks Industry Rank Education -- Learn more about the Zacks Industry Rank

Top 28% (70 out of 250)

Industry: Medical - Products

Zacks Premium FeatureView All Zacks #1 Ranked Stocks

Better trading starts here.

Zacks News

PetIQ, Inc. (PETQ) Hits Fresh High: Is There Still Room to Run?

by Zacks Equity Research

PetIQ (PETQ) is at a 52-week high, but can investors hope for more gains in the future? We take a look at the company's fundamentals for clues.

PBH Stock Might Get a Boost From Focused Brand-Building Efforts

by Zacks Equity Research

Prestige Consumer puts emphasis on brand building and product innovation in niche consumer healthcare categories to improve the lives of its consumers.

PBH or SYK: Which Is the Better Value Stock Right Now?

by Zacks Equity Research

PBH vs. SYK: Which Stock Is the Better Value Option?

Here's Why 'Trend' Investors Would Love Betting on Prestige Consumer Healthcare (PBH)

by Zacks Equity Research

Prestige Consumer Healthcare (PBH) could be a solid choice for shorter-term investors looking to capitalize on the recent price trend in fundamentally sound stocks. It is one of the many stocks that passed through our shorter-term trading strategy-based screen.

Prestige Consumer's (PBH) Q1 Earnings Beat, Margins Shrink

by Zacks Equity Research

Prestige Consumer (PBH) first-quarter sales bear the brunt of the ongoing supply chain challenges in the Clear Eyes business.

Prestige Consumer Healthcare (PBH) Reports Q1 Earnings: What Key Metrics Have to Say

by Zacks Equity Research

Although the revenue and EPS for Prestige Consumer Healthcare (PBH) give a sense of how its business performed in the quarter ended June 2024, it might be worth considering how some key metrics compare with Wall Street estimates and the year-ago numbers.

Prestige Consumer Healthcare (PBH) Beats Q1 Earnings and Revenue Estimates

by Zacks Equity Research

Prestige Consumer Healthcare (PBH) delivered earnings and revenue surprises of 4.65% and 2.72%, respectively, for the quarter ended June 2024. Do the numbers hold clues to what lies ahead for the stock?

PetIQ (PETQ) Tops Q2 Earnings Estimates

by Zacks Equity Research

PetIQ (PETQ) delivered earnings and revenue surprises of 42.86% and 12.02%, respectively, for the quarter ended June 2024. Do the numbers hold clues to what lies ahead for the stock?

OraSure Technologies (OSUR) Tops Q2 Earnings and Revenue Estimates

by Zacks Equity Research

OraSure (OSUR) delivered earnings and revenue surprises of 133.33% and 1.86%, respectively, for the quarter ended June 2024. Do the numbers hold clues to what lies ahead for the stock?

Seeking Clues to Prestige Consumer Healthcare (PBH) Q1 Earnings? A Peek Into Wall Street Projections for Key Metrics

by Zacks Equity Research

Evaluate the expected performance of Prestige Consumer Healthcare (PBH) for the quarter ended June 2024, looking beyond the conventional Wall Street top-and-bottom-line estimates and examining some of its key metrics for better insight.

LeMaitre Vascular (LMAT) Surpasses Q2 Earnings and Revenue Estimates

by Zacks Equity Research

LeMaitre (LMAT) delivered earnings and revenue surprises of 10.64% and 1.25%, respectively, for the quarter ended June 2024. Do the numbers hold clues to what lies ahead for the stock?

AHCO or PBH: Which Is the Better Value Stock Right Now?

by Zacks Equity Research

AHCO vs. PBH: Which Stock Is the Better Value Option?

Prestige Consumer Healthcare (PBH) Down 0.4% Since Last Earnings Report: Can It Rebound?

by Zacks Equity Research

Prestige Consumer Healthcare (PBH) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.

Prestige Consumer (PBH) Q4 Earnings Miss, Operating Margin Falls

by Zacks Equity Research

Prestige Consumer's (PBH) Q4 business suffers from supply chain pressure that impacts its ability to fulfill retailer orders.

Prestige Consumer Healthcare (PBH) Reports Q4 Earnings: What Key Metrics Have to Say

by Zacks Equity Research

Although the revenue and EPS for Prestige Consumer Healthcare (PBH) give a sense of how its business performed in the quarter ended March 2024, it might be worth considering how some key metrics compare with Wall Street estimates and the year-ago numbers.

Prestige Consumer Healthcare (PBH) Misses Q4 Earnings and Revenue Estimates

by Zacks Equity Research

Prestige Consumer Healthcare (PBH) delivered earnings and revenue surprises of -10.53% and 3.46%, respectively, for the quarter ended March 2024. Do the numbers hold clues to what lies ahead for the stock?

Shaun Pruitt headshot

2 Intriguing Medical Stocks to Buy for Steady Growth as Earnings Approach

by Shaun Pruitt

Among the medical sector, Alcon (ALC) and Prestige Consumer Healthcare (PBH) are two intriguing stocks to buy for growth as their quarterly results approach on Tuesday, May 14.

BioLife Solutions, Inc. (BLFS) Reports Q1 Loss, Tops Revenue Estimates

by Zacks Equity Research

BioLife Solutions (BLFS) delivered earnings and revenue surprises of 26.92% and 8.28%, respectively, for the quarter ended March 2024. Do the numbers hold clues to what lies ahead for the stock?

Unveiling Prestige Consumer Healthcare (PBH) Q4 Outlook: Wall Street Estimates for Key Metrics

by Zacks Equity Research

Beyond analysts' top -and-bottom-line estimates for Prestige Consumer Healthcare (PBH), evaluate projections for some of its key metrics to gain a better insight into how the business might have performed for the quarter ended March 2024.

Will Cresco Labs Inc. (CRLBF) Report Negative Earnings Next Week? What You Should Know

by Zacks Equity Research

Cresco Labs Inc. (CRLBF) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

IM Cannabis Corp. (IMCC) Reports Q1 Loss, Tops Revenue Estimates

by Zacks Equity Research

IM Cannabis (IMCC) delivered earnings and revenue surprises of 0% and 14.14%, respectively, for the quarter ended March 2024. Do the numbers hold clues to what lies ahead for the stock?

Why This 1 Value Stock Could Be a Great Addition to Your Portfolio

by Zacks Equity Research

Whether you're a value, growth, or momentum investor, finding strong stocks becomes easier with the Zacks Style Scores, a top feature of the Zacks Premium research service.

PBH vs. ABT: Which Stock Is the Better Value Option?

by Zacks Equity Research

PBH vs. ABT: Which Stock Is the Better Value Option?

Prestige Consumer Healthcare (PBH) Earnings Expected to Grow: What to Know Ahead of Q4 Release

by Zacks Equity Research

Prestige Consumer Healthcare (PBH) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

Here's Why You Should Retain Prestige Consumer (PBH) Stock Now

by Zacks Equity Research

The robust strength of Prestige Consumer's (PBH) diversified portfolio bodes well for investors.